Armani Orihuela, MD
Family Medicine · Sarasota, FLNPI 1013443506
Payments from drug & device makers
Across 599 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$1K
- Pfizer$1K
- Bayer$792
- GSK$737
- Sumitomo Pharma America, Inc.$627
- plus $5K from 43 others
What the payments were for
- Food & beverage$10,297100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,297 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $202,167 |
| MounjaroTirzepatide | 153 | $171,466 |
| JardianceEmpagliflozin | 74 | $108,392 |
| OzempicSemaglutide | 65 | $82,163 |
| XareltoRivaroxaban | 48 | $59,713 |
| TrulicityDulaglutide | 43 | $56,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $49,227 |
| JanuviaSitagliptin Phosphate | 37 | $41,652 |
| EntrestoSacubitril/Valsartan | 36 | $40,723 |
| FarxigaDapagliflozin Propanediol | 30 | $35,855 |
| GemtesaVibegron | 21 | $17,564 |
| MyrbetriqMirabegron | 17 | $15,458 |
| LinzessLinaclotide | 14 | $11,212 |
| Atorvastatin Calcium | 749 | $6,653 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,168 | $228,177196 claims |
| PfizerEliquis | $1,018 | $202,167169 claims |
| Boehringer IngelheimJardiance | $331 | $108,39274 claims |
| Novo NordiskOzempic | $559 | $82,16365 claims |
| Johnson & JohnsonXarelto | $43 | $59,71348 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $737 | $54,43183 claims |
| MerckJanuvia | $548 | $41,65237 claims |
| NovartisEntresto | $198 | $40,72336 claims |
| AstraZenecaFarxiga | $450 | $35,85530 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $627 | $17,56421 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $15,45817 claims |
| AbbVieLinzess, Synthroid | $1,141 | $14,25345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Sarasota
- Niaz AusafSarasota$3.8M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.